Dr. Korde is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
5255 Loughboro Rd NW
Washington, DC 20016Phone+1 301-402-2183Fax+1 301-496-1854
Education & Training
National Institutes of Health Clinical CenterFellowship, Medical Oncology, 2002 - 2004
MedStar Health/Georgetown University HospitalResidency, Internal Medicine, 1998 - 2001
New York Medical CollegeClass of 1998
Certifications & Licensure
MD State Medical License 2019 - 2026
DC State Medical License 2001 - 2024
WA State Medical License 2009 - 2020
VA State Medical License 1998 - 2001- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- Regional Top Doctor Castle Connolly, 2014
Clinical Trials
- Zoledronate or Observation in Maintaining Bone Mineral Density in Patients Who Are Undergoing Surgery to Remove Both Ovaries Start of enrollment: 2005 Nov 28
- I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer Start of enrollment: 2010 Mar 01
- Low-Dose Tamoxifen Citrate in Reducing Breast Cancer Risk in Radiation-Induced Cancer Survivors Start of enrollment: 2010 Sep 01
- Join now to see all
Publications & Presentations
PubMed
- 112 citationsEndocrine Treatment and Targeted Therapy for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer: ASCO Guideline Update.Harold J. Burstein, Mark R. Somerfield, Debra L. Barton, Ali Dorris, Lesley Fallowfield
Journal of Clinical Oncology. 2021-07-29 - 388 citationsEndocrine Therapy for Hormone Receptor–Positive Metastatic Breast Cancer: American Society of Clinical Oncology GuidelineHope S. Rugo, R. Bryan Rumble, Erin Macrae, Debra L. Barton, Hannah Klein Connolly
Journal of Clinical Oncology. 2016-09-27 - 7 citationsAre we assuming too much with our statistical assumptions? Lessons learned from the ALTTO trial.Eileen Holmes, Ian Bradbury, L.S. Williams, Larissa A. Korde, E. de Azambuja
Annals of Oncology. 2019-09-01
Journal Articles
- Prognostic Gene Expression Profiling in Cutaneous MelanomaDouglas Grossman, Sancy A Leachman, Larissa Korde, Elizabeth I Buchbinder, Emily Y Chu, Julia A Curtis, Laura K Ferris, Kenneth F Grossmann, Siwen Hu-Lieskovan, Joanne..., JAMA Dermatology
Authored Content
- Prognostic Gene Expression Profiling in Cutaneous MelanomaJuly 2020
- Prognostic Gene Expression Profiling in Cutaneous MelanomaJuly 2020
- Prognostic Gene Expression Profiling in Cutaneous MelanomaJuly 2020
Press Mentions
Neoadjuvant Immunotherapy Improves Outlook in High-Risk MelanomaFebruary 24th, 2023- A Safer, Better Treatment Option for Some Younger Women With Breast CancerJanuary 11th, 2023
- Neoadjuvant Immunotherapy Improves Outlook in High-Risk MelanomaSeptember 11th, 2022
- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
